This company is seriously on the turnaround with a very nice...

This company is seriously on the turnaround with a very nice drug pipeline in place after this acquisition. Even at these prices and a market cap of 7 mill the potential upside here is now massive. Dr Robert Combie has put a transformation in place here with recent acquisitions with the latest really showing some huge potential with US cancer centres already dosing patients. Compared with peers at same or lesser development and with less drug pipelines this would have to be one of the most undervalued plays on our biotech market with potential. Nice to see US government involved in trial funding bit like NEU's US army involvement with their trial funding. At about all time lows the only way is up here and very significantly i believe in coming months and into 2015.